buccal semaglutide ACC 2025: Oral Reduces Cardiovascular Events by 14% at 4 Years Everything You Need To Know

2023;18:e0294236

Who Responded Best Subgroup analysis from the trials identified several factors associated with stronger response

Cell Metabolism, 35(2), 253273

Funding The authors certify that they or their institutions did not receive any support (e.g., grants, funding, payment, or other benefits) or a commitment or agreement to provide such benefits in connection with the research or preparation of this manuscript, except as disclosed in a separate attachment

Semaglutide is in a category of prescription drugs called glucagon-like peptide-1 agonists, or GLP-1s, and they have upended the way obesity is treated